Suhasini R. Gopal

Suhasini R. Gopal

Auto-generated profile, based on publicly available information

Suhasini R. Gopal

Department of Otolaryngology - HNS, Case Western Reserve University, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RGRuishuang Geng
Ruishuang Geng
AOAkil Omar
Akil Omar
SGSuhasini R. Gopal
Suhasini R. Gopal
DCDaniel H.-C. Chen
Daniel H.-C. Chen
RSRuben Stepanyan
Ruben Stepanyan
KAKumar N. Alagramam
Kumar N. Alagramam
Usher syndrome type III (USH3) characterized by progressive loss of vision and hearing is caused by mutations in the clarin-1 gene (CLRN1). Clrn1 knockout (KO) mice develop hair cell defects by postnatal day 2 (P2) and are deaf by P21-P25. Early onset profound hearing loss in KO mice and lack of information about the cochlear cell type that requires Clrn1 expression pose challenges to therapeutic investigation. We generated KO mice harboring a transgene, TgAC1, consisting of Clrn1-UTR (Clrn1 cDNA including its 5′ and 3′ UTR) under the control of regulatory elements (Atoh1 3′ enhancer/β-globin basal promoter) to direct expression of Clrn1 in hair cells during development and down regulate it postnatally. The KO-TgAC1 mice displayed delayed onset progressive hearing loss associated with deterioration of the hair bundle structure, leading to the hypothesis that hair cell expression of Clrn1 is essential for postnatal preservation of hair cell structure and hearing. Consistent with that hypothesis, perinatal transfection of hair cells in KO-TgAC1 mice with a single injection of AAV-Clrn1-UTR vector showed correlative preservation of the hair bundle structure and hearing through adult life. Further, the efficacy of AAV-Clrn1 vector was significantly attenuated, revealing the potential importance of UTR in gene therapy.

6 March 2013 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
RGRuishuang Geng
Ruishuang Geng
MSMarcos Sotomayor
Marcos Sotomayor
KKKimberly J. Kinder
Kimberly J. Kinder
SGSuhasini R. Gopal
Suhasini R. Gopal
JGJohn Gerka-Stuyt
John Gerka-Stuyt
KAKumar N. Alagramam
Kumar N. Alagramam
In hair cells of the inner ear, sound or head movement increases tension in fine filaments termed tip links, which in turn convey force to mechanosensitive ion channels to open them. Tip links are formed by a tetramer of two cadherin proteins: protocadherin 15 (PCDH15) and cadherin 23 (CDH23), which have 11 and 27 extracellular cadherin (EC) repeats, respectively. Mutations in either protein cause inner ear disorders in mice and humans. We showed recently that these two cadherins bind tip-to-tip in a “handshake” mode that involves the EC1 and EC2 repeats of both proteins. However, a paucity of appropriate animal models has slowed our understanding both of the interaction and of how mutations of residues within the predicted interface compromise tip link integrity. Here, we presentnoddy, a new mouse model for hereditary deafness. Identified in a forward genetic screen,noddyhomozygotes lack inner ear function. Mapping and sequencing showed thatnoddymutant mice harbor an isoleucine-to-asparagine (I108N) mutation in the EC1 repeat of PCDH15. Residue I108 interacts with CDH23 EC2 in the handshake and its mutation impairs the interactionin vitro. Thenoddymutation allowed us to determine the consequences of blocking the handshakein vivo: tip link formation and bundle morphology are disrupted, and mechanotransduction channels fail to remain open at rest. These results offer new insights into the interaction between PCDH15 and CDH23 and help explain the etiology of human deafness linked to mutations in the tip-link interface.

15 July 2015 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SGSuhasini R. Gopal
Suhasini R. Gopal
DCDaniel H.-C. Chen
Daniel H.-C. Chen
SCShih-Wei Chou
Shih-Wei Chou
JZJingjing Zang
Jingjing Zang
SNStephan Neuhauss
Stephan Neuhauss
KAKumar N. Alagramam
Kumar N. Alagramam
Usher syndrome type III (USH3) is characterized by progressive loss of hearing and vision, and varying degrees of vestibular dysfunction. It is caused by mutations that affect the human clarin-1 protein (hCLRN1), a member of the tetraspanin protein family. The missense mutation CLRN1N48K, which affects a conserved N-glycosylation site in hCLRN1, is a common causative USH3 mutation among Ashkenazi Jews. The affected individuals hear at birth but lose that function over time. Here, we developed an animal model system using zebrafish transgenesis and gene targeting to provide an explanation for this phenotype. Immunolabeling demonstrated that Clrn1 localized to the hair cell bundles (hair bundles). The clrn1 mutants generated by zinc finger nucleases displayed aberrant hair bundle morphology with diminished function. Two transgenic zebrafish that express either hCLRN1 or hCLRN1N48K in hair cells were produced to examine the subcellular localization patterns of wild-type and mutant human proteins. hCLRN1 localized to the hair bundles similarly to zebrafish Clrn1; in contrast, hCLRN1N48K largely mislocalized to the cell body with a small amount reaching the hair bundle. We propose that this small amount of hCLRN1N48K in the hair bundle provides clarin-1-mediated function during the early stages of life; however, the presence of hCLRN1N48K in the hair bundle diminishes over time because of intracellular degradation of the mutant protein, leading to progressive loss of hair bundle integrity and hair cell function. These findings and genetic tools provide an understanding and path forward to identify therapies to mitigate hearing loss linked to the CLRN1 mutation. SIGNIFICANCE STATEMENT Mutations in the clarin-1 gene affect eye and ear function in humans. Individuals with the CLRN1N48K mutation are born able to hear but lose that function over time. Here, we develop an animal model system using zebrafish transgenesis and gene targeting to provide an explanation for this phenotype. This approach illuminates the role of clarin-1 and the molecular mechanism linked to the CLRN1N48K mutation in sensory hair cells of the inner ear. Additionally, the investigation provided an in vivo model to guide future drug discovery to rescue the hCLRN1N48K in hair cells.

25 April 2016 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
KAKumar N Alagramam
Kumar N Alagramam
SGSuhasini R Gopal
Suhasini R Gopal
RGRuishuang Geng
Ruishuang Geng
DCDaniel H-C Chen
Daniel H-C Chen
INIna Nemet
Ina Nemet
YIYoshikazu Imanishi
Yoshikazu Imanishi
A small molecule identified from high-throughput screening and optimization specifically stabilizes a disease-linked CLRN1 protein, delivering it to its site of action at the plasma membrane and preserving hearing in a new mouse model for Usher syndrome type III. Usher syndrome type III (USH3), characterized by progressive deafness, variable balance disorder and blindness, is caused by destabilizing mutations in the gene encoding the clarin-1 (CLRN1) protein. Here we report a new strategy to mitigate hearing loss associated with a common USH3 mutation CLRN1N48K that involves cell-based high-throughput screening of small molecules capable of stabilizing CLRN1N48K, followed by a secondary screening to eliminate general proteasome inhibitors, and finally an iterative process to optimize structure–activity relationships. This resulted in the identification of BioFocus 844 (BF844). To test the efficacy of BF844, we developed a mouse model that mimicked the progressive hearing loss associated with USH3. BF844 effectively attenuated progressive hearing loss and prevented deafness in this model. Because the CLRN1N48K mutation causes both hearing and vision loss, BF844 could in principle prevent both sensory deficiencies in patients with USH3. Moreover, the strategy described here could help identify drugs for other protein-destabilizing monogenic disorders.

2 September 2010 in Legal Medicine
Verified
Journal Article
Closed access
PDF file
KBKuppareddi Balamurugan
Kuppareddi Balamurugan
SKS. Kanthimathi
S. Kanthimathi
MVM. Vijaya
M. Vijaya
GSG. Suhasini
G. Suhasini
GDGeorge Duncan
George Duncan
BBBruce Budowle
Bruce Budowle

12 December 2017 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
JVJonathon W. Vargo
Jonathon W. Vargo
SWSteven N. Walker
Steven N. Walker
SGSuhasini R. Gopal
Suhasini R. Gopal
ADAditi R. Deshmukh
Aditi R. Deshmukh
BJBrian M. McDermott Jr.
Brian M. McDermott Jr.
RSRuben Stepanyan
Ruben Stepanyan
Cisplatin and other related platinum antineoplastic drugs are commonly used in the treatment of a variety of cancers in both adults and children but are often associated with severe side effects, including hearing loss. Cisplatin’s ototoxic effects are multifaceted, culminating in irreversible damage to the mechanosensory hair cells in the inner ear. Platinum drugs act on cancerous cells by forming nuclear DNA adducts, which may initiate signaling leading to cell cycle arrest or apoptosis. Moreover, it was reported that cisplatin may induce mitochondrial DNA damage in non-cancerous cells. Therefore, protecting mitochondria may alleviate cisplatin-induced insult to non-proliferating cells. Thus, it is important to identify agents that shield the mitochondria from cisplatin-induced insult without compromising the anti-tumor actions of the platinum-based drugs. In this study we tested the protective properties of mitochondrial division inhibitor, mdivi-1, a derivative of quinazolinone and a regulator of mitochondrial fission. Interestingly, it has been reported that mdivi-1 increases the apoptosis of cells that are resistant to cisplatin. The ability of mdivi-1 to protect hair cells against cisplatin-induced toxicity was evaluated in a fish model. Wild-type (Tübingen strain), cdh23 mutant, and transgenic pvalb3b::GFP zebrafish stably expressing GFP in the hair cells were used in this study. Larvae at 5–6 days post fertilization were placed in varying concentrations of cisplatin (50–200 μM) and/or mdivi-1 (1–10 μM) for 16 h. To evaluate hair cell’s viability the number of hair bundles per neuromast were counted. To assess hair cell function, we used the FM1-43 uptake assay and recordings of neuromast microphonic potentials. The results showed that mdivi-1 protected hair cells of lateral line neuromasts when they were challenged by 50 μM of cisplatin: viability of hair cells increased almost twice from 19% ± 1.8% to 36% ± 2.0% (p < 0.001). No protection was observed when higher concentrations of cisplatin were used. In addition, our data were in accord with previously reported results that functional mechanotransduction strongly potentiates cisplatin-induced hair cell toxicity. Together, our results suggest that mitochondrial protection may prevent cisplatin-induced damage to hair cells.